Medications received by patients with juvenile dermatomyositis

Seminars in Arthritis and Rheumatism
Takayuki KishiChildhood Myositis Heterogeneity Study Group

Abstract

Few controlled studies are available to guide treatment decisions in juvenile dermatomyositis (JDM). This study evaluated therapies received, changes of treatment over time, and factors associated with medication choices in JDM. We performed a retrospective analysis of the number and type of therapies and duration of treatment for 320 patients with JDM enrolled in a North American registry. Kaplan-Meier and logistic regression analysis were used to assess the association of demographic and clinical features and autoantibodies with medication usage. High-dose oral prednisone was the primary therapy given to 99% of patients. 1997 was determined to be a threshold year for increasing usage of medications other than prednisone. The median time to half the initial oral prednisone dose was shorter in patients diagnosed after vs. before 1997 (10 vs. 19 months, P < 0.01). Patients received intravenous methylprednisolone (IVMP), methotrexate, intravenous immunoglobulin, antimalarial drugs, and combination therapy more frequently when diagnosed after 1997. IVMP was frequently received by patients with severe illness onset, anti-p155/140 (anti-TIF1) and anti-MJ (anti-NXP2) autoantibodies. Treatment with methotrexate was associated with old...Continue Reading

Citations

Oct 12, 2018·Expert Review of Clinical Immunology·Adam M Huber
Apr 26, 2019·Annals of the Rheumatic Diseases·Sara SabbaghUNKNOWN Childhood Myositis Heterogeneity Collaborative Study Group
Aug 17, 2019·The Journal of Rheumatology·Weng Ian CheMarie Holmqvist
Jan 24, 2019·International Journal of Molecular Sciences·Giovanna FerraraRolando Cimaz
Oct 18, 2020·Rheumatology·Takayuki KishiUNKNOWN with the Childhood Myositis Heterogeneity Study Group
Nov 4, 2020·Rheumatology·Gulnara MamyrovaUNKNOWN Childhood Myositis Heterogeneity Collaborative Study Group
Apr 15, 2021·Clinical Rheumatology·Sara E SabbaghUNKNOWN Johns Hopkins Myositis Center Group
Aug 7, 2021·Current Treatment Options in Rheumatology·Lauren M PachmanAmer M Khojah
Jul 8, 2021·Current Opinion in Rheumatology·Hanna Kim
Apr 28, 2021·Current Pediatric Reviews·Alexander K C LeungAlex H C Wong

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimalarial Agents (ASM)

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.

Antimalarial Agents

Antimalarial agents, also known as antimalarials, are designed to prevent or cure malaria. Discover the latest research on antimalarial agents here.